Nissha Co., Ltd.
Financial Summary for the Third Quarter of the Fiscal Year Ending December 2026 [IFRS] (Consolidated) [Summary]
Net sales were 144,980 million yen (YoY -0.2%), operating loss was 3,679 million yen, and quarterly net loss was 5,773 million yen. Full-year forecasts were revised; impacts related to USM continue. Segment-wise, medical device CDMO and similar businesses were firm, while Devices and Industrial Materials were affected. Dividend policy is maintained. An investor meeting for institutional investors is scheduled for November 11, 2026.
Key Figures
- Net Sales: 144,980 million yen (YoY -0.2%)
- Operating Loss: -3,679 million yen
- Quarterly Profit: 827 million yen (Quarterly profit attributable to owners of the parent)
- Full-Year Net Sales Forecast: 195,000 million yen (0.1% increase)
- Dividend: 25 yen at end of Q1, 25 yen at end of Q2, total 50 yen for the year
AI要約
Overview of Performance
For the third quarter of the fiscal year ending December 2026, Nissha Co., Ltd. reported net sales near flat year-on-year. Some segments performed steadily, but the overall result was an operating loss due to weakness in the Devices segment and external factors. In particular, goodwill impairment related to USM and increased production costs for exterior parts weighed on results, turning net income negative. The full-year forecast has been revised, and an investor meeting for institutional investors is scheduled for November 11, 2026.
Outlook and Impact on Shareholders
While revisions to the full-year forecast are in place, the strength in the medical device CDMO business is expected to provide support. However, demand weakness in Devices and rising costs in Industrial Materials may continue. The current dividend policy remains unchanged, with the recent dividend maintained at 50 yen per year (25 yen x 2). Preventing recurring goodwill impairments and improving productivity are identified as key issues.
Nissha Co., Ltd.
Company overview · Stock price · Financial data · All IR
